• Fri, May 24, 2019
  • Tue, May 28, 2019
  • Thu, May 30, 2019
  • Wed, May 29, 2019

Brian Abrahams Downgraded (BCRX) to Hold and Decreased Target to $4.5 on, May 24th, 2019

Brian Abrahams of RBC Capital, Downgraded "BioCryst Pharmaceuticals, Inc." (BCRX) to Hold and Decreased Target from $16 to $4.5 on, May 24th, 2019.

Brian has made no other calls on BCRX in the last 4 months.



There is 1 other peer that has a rating on BCRX. Out of the 1 peers that are also analyzing BCRX, all agrees with Brian's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • Gena Wang of "Barclays" Maintained at Hold with Increased Target to $8 on, Tuesday, April 2nd, 2019